November 06, 2015 – Just about the same time at the End of October 2015, the American Drug and Food Administration (FDA) has approved, and the European Medicines Agency (EMA) has recommended for approval Talimogene Laherparepvec (Imlygic), a first-in-class advanced therapy medicinal product (ATMP) derived from a …

Imlygic, a first-of-its-kind oncolytic immunotherapy for the treatment of melanoma Read more »

April 30, 2014 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for Mekinist (trametinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E mutation. Mekinist …

European Medicines Agency (EMA) recommends approval of Trametinib [Mekinist] for the treatment of melanoma with a BRAF V600E mutation Read more »